Ovid Therapeutics Reports Q3 2025 Revenue Decline and Net Loss Amid Increased Year-to-Date Revenue

Ovid Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $132,000 for the three months ended September 30, 2025, a decrease from $173,000 in the same period of the previous year. For the nine months ended September 30, 2025, the company generated $6.5 million in revenue, significantly up from $490,000 in the prior year, primarily due to increased royalties from licensing agreements. Despite this revenue growth, Ovid recorded a net loss of $12.2 million for the third quarter and $27.1 million for the nine-month period, compared to losses of $14 million and $17.2 million, respectively, in the same periods of 2024.

The company’s operating expenses for the third quarter totaled $12.7 million, a slight decrease from $13.4 million in the prior year, driven by reduced research and development costs, which fell to $5.9 million from $7.9 million. This reduction is attributed to the pause in the OV888 (GV101) program and cost-cutting measures implemented following an organizational restructuring. General and administrative expenses increased to $6.8 million from $5.5 million, largely due to higher professional fees associated with business development activities.

Ovid's financial position showed a decline in total assets, which decreased to $63.8 million as of September 30, 2025, down from $92.2 million at the end of 2024. The company reported $20.6 million in cash and cash equivalents, alongside $4.9 million in marketable securities. The accumulated deficit reached $331.4 million, reflecting the ongoing challenges in achieving profitability. The company’s working capital stood at $22 million, indicating a need for continued funding to support its operations and development programs.

In terms of strategic developments, Ovid completed a private placement on October 2, 2025, raising approximately $75.7 million in net proceeds through the issuance of convertible preferred stock and warrants. This funding is expected to support the company’s operations for at least the next 12 months. Additionally, Ovid announced positive topline data from a Phase 1 trial for its GABA-aminotransferase inhibitor, OV329, which may enhance its product pipeline targeting neurological conditions.

Looking ahead, Ovid anticipates continued operating losses as it advances its drug candidates through clinical trials and seeks to expand its portfolio. The company remains focused on securing additional funding through equity offerings, collaborations, and licensing agreements to sustain its operations and development efforts in the biopharmaceutical sector.